Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The ubiquitin/proteasome pathway is crucial for protein degradation.
• NEDD8-activating enzyme initiates the neddylation pathway, impacting protein degradation.
• Cullin neddylation is essential for the activity of cullin-ring ligases.

Purpose of the Study:

• To investigate the efficacy of MLN4924, a NEDD8-activating enzyme inhibitor, in preclinical multiple myeloma models.
• To assess MLN4924's activity against various multiple myeloma cell lines, including resistant ones.
• To evaluate MLN4924's therapeutic potential in combination with existing multiple myeloma treatments.

Main Methods:

• In vitro studies using multiple myeloma cell lines to determine MLN4924's dose-dependent effects on viability.
• Testing MLN4924 against bortezomib-resistant and sensitive cell lines.
• Assessing MLN4924's activity in primary patient cells and in combination therapy.
• In vivo studies using mouse models (subcutaneous and orthotopic) to evaluate MLN4924's effect on tumor burden.

Main Results:

• MLN4924 demonstrated dose-dependent cytotoxicity in multiple myeloma cell lines (EC50 = 25-150 nmol/L).
• The inhibitor was effective against bortezomib-resistant cell lines and primary patient cells (EC50 <500 nmol/L).
• MLN4924 showed additive effects with dexamethasone, doxorubicin, and bortezomib, and reduced tumor burden in vivo.
• MLN4924 treatment did not induce the compensatory upregulation of ubiquitin/proteasome transcripts seen with bortezomib.

Conclusions:

• MLN4924 is a potent inhibitor of NEDD8-activating enzyme with significant preclinical activity in multiple myeloma.
• MLN4924 exhibits efficacy across diverse multiple myeloma models, including resistant and primary patient cells.
• These findings support the clinical investigation of MLN4924 for multiple myeloma treatment.